Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $13.50.
A number of brokerages recently commented on ACRV. Jefferies Financial Group restated a “buy” rating on shares of Acrivon Therapeutics in a report on Wednesday, November 11th. Weiss Ratings raised Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Citizens Jmp restated a “market outperform” rating on shares of Acrivon Therapeutics in a report on Tuesday. Finally, Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th.
Get Our Latest Stock Analysis on ACRV
Acrivon Therapeutics Trading Up 0.6%
Shares of ACRV stock traded up $0.01 on Tuesday, hitting $1.47. The stock had a trading volume of 52,929 shares, compared to its average volume of 788,110. Acrivon Therapeutics has a twelve month low of $1.27 and a twelve month high of $3.56. The company has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $1.74. The firm has a market cap of $62.95 million, a P/E ratio of -0.79 and a beta of 1.96.
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. On average, analysts expect that Acrivon Therapeutics will post -1.71 earnings per share for the current year.
Insider Buying and Selling
In other Acrivon Therapeutics news, CEO Peter Blume-Jensen sold 14,036 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total transaction of $31,019.56. Following the completion of the transaction, the chief executive officer owned 2,230,052 shares of the company’s stock, valued at $4,928,414.92. This represents a 0.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 14,843 shares of company stock valued at $32,549. Insiders own 10.50% of the company’s stock.
Institutional Trading of Acrivon Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in ACRV. Marshall Wace LLP boosted its holdings in Acrivon Therapeutics by 2.0% during the third quarter. Marshall Wace LLP now owns 542,344 shares of the company’s stock worth $1,112,000 after purchasing an additional 10,488 shares during the last quarter. StoneX Group Inc. acquired a new position in shares of Acrivon Therapeutics during the 3rd quarter worth about $43,000. Spark Investment Management LLC acquired a new position in shares of Acrivon Therapeutics during the 2nd quarter worth about $50,000. Empowered Funds LLC acquired a new position in shares of Acrivon Therapeutics during the 3rd quarter worth about $117,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Acrivon Therapeutics by 19.6% in the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock valued at $1,054,000 after acquiring an additional 124,271 shares in the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.
Acrivon Therapeutics Company Profile
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.
Featured Stories
- Five stocks we like better than Acrivon Therapeutics
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
